- Details
For academic groups or small biotech companies primarily focused on drug discovery, taking products into clinical development can be a daunting task. The requirements for process development and analytical development which enable GMP manufacturing can appear to be extremely expensive steps in the development path. This article highlights how investment in early-phase process and analytical development can significantly increase the value of products in clinical development, as well as increasing the value of the sponsor company.
Read more: ADDING VALUE THROUGH EARLY-PHASE PROCESS AND ANALYTICAL DEVELOPMENT